Oral anticoagulant use around the time of atrial fibrillation ablation: A review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis

Journal of Cardiovascular Electrophysiology

Volumn 25, Issue 12, 2014, Pages 1411-1418

  Garton, Alex B ^a   Dudzinski, John ^a,b   Kowey, Peter R ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

atrial fibrillation; atrial fibrillation ablation; novel oral anticoagulants; thromboembolic prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DRONEDARONE; EDOXABAN; HEPARIN; KETOCONAZOLE; RIVAROXABAN; WARFARIN;

ABLATION THERAPY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG HALF LIFE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAXIMUM PLASMA CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; THROMBOEMBOLISM; ADVERSE EFFECTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COMPLICATION; EVIDENCE BASED MEDICINE; ORAL DRUG ADMINISTRATION; PREMEDICATION; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; EVIDENCE-BASED MEDICINE; HUMANS; PREMEDICATION; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84926420010     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12546     Document Type: Article

References (42)

1. Naccarelli GV, Varker H, Lin J, Schulman KL,: Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-1539.
2. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW,: AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 2014: doi: 10.1016/j.jacc.2014.03.022.
3. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J,: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
4. Kneeland PP, Fang MC,: Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med Off Publ Soc Hosp Med 2009; 4: E1-5.
5. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E,: Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
6. ClinicalTrials.gov: Catheter ablation vs anti-arrhythmic drug therapy for atrial fibrillation trial (CABANA) [Internet]. 2009 [cited 2013 Sep 9]. Available from: http://clinicaltrials.gov/ct2/show/NCT00911508
7. Guiot A, Jongnarangsin K, Chugh A, Suwanagool A, Latchamsetty R, Myles JD, Jiang Q, Crawford T, Good E, Pelosi F, Bogun F, Morady F, Oral H,: Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly. J Cardiovasc Electrophysiol 2012; 23: 36-43.
8. Jani SM, Gosch K, Schneider P, Shore S, Bradley S, Maddox T, Chen J,: Uptake of novel oral anticoagulants in patients with non-valvular and valvular atrial fibrillation: Results from the NCDR-PINNACLE Registry. J Am Coll Cardiol [Internet]. 2014; 63: doi: 10.1016/S0735-1097(14).
9. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen S-A, Crijns HJG, Damiano RJ, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim Y-H, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao H-M, Wilber D, Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation: 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 9: 632-696.e21.
10. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P,: EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2013; 34: 2094-2106.
11. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L, Martin DO, Kanj M, Arruda M, Cummings J, Schweikert R, Saliba W, Natale A,: Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531-2534.
12. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O, Banna M, Williams-Andrews M, Sherman M, Kanj M, Bhargava M, Dresing T, Callahan T, Tchou P, Di Biase L, Beheiry S, Lindsay B, Natale A, Wazni O,: Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009; 6: 1425-1429.
13. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, Verma A, Khaykin Y, Hongo R, Hao S, Beheiry S, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Santangeli P, Wang P, Al-Ahmad A, Patel D, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Cummings JE, Schweikert RA, Lewis WR, Natale A,: Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556.
14. Page SP, Siddiqui MS, Finlay M, Hunter RJ, Abrams DJ, Dhinoja M, Earley MJ, Sporton SC, Schilling RJ,: Catheter ablation for atrial fibrillation on uninterrupted warfarin: Can it be done without echo guidance? J Cardiovasc Electrophysiol 2011; 22: 265-270.
15. Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, Koplan BA, McCLENNEN S, Michaud GF,: Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22: 248-254.
16. Hakalahti A, Uusimaa P, Ylitalo K, Raatikainen MJP,: Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 2011; 13: 640-645.
17. Gopinath D, Lewis WR, Biase LD, Natale A,: Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: Special considerations. J Cardiovasc Electrophysiol 2011; 22: 236-239.
18. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA,: The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
19. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A,: Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2012; 59: 1168-1174.
20. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS,: Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol 2014; 113: 1173-1177.
21. Providencia R, Albenque J-P, Combes S, Bouzeman A, Casteigt B, Combes N, Narayanan K, Marijon E, Boveda S,: Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Heart 2014; 100: 324-335.
22. Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE, Garbati MA, Bahmaid RA, Wimmer AP,: Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Europace 2013; 15: 1412-1420.
23. Hohnloser SH, Camm AJ,: Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: A meta-analysis of the literature. Europace 2013; 15: 1407-1411.
24. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, Lindsay BD, Wazni O,: Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013; 6: 460-466.
25. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, Gunter A, Mcelderry HT,: Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation: dabigatran versus warfarin for af ablation. J Cardiovasc Electrophysiol 2013; 24: 861-865.
26. Kim J-S, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, Crawford T, Suwanagool A, Sinno M, Carrigan T, Kennedy R, Saint-Phard W, Yokokawa M, Good E, Bogun F, Pelosi F, Morady F, Oral H,: Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013; 10: 483-489.
27. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y, Hirayama H, Murohara T,: A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013; 36: 172-179.
28. Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, Daubert JP, Piccini JP,: Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: A meta-analysis of observational studies. J Interv Card Electrophysiol 2013; 37: 213-221.
29. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM,; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
30. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KAA, Mahaffey KW,: Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2013; 61: 651-658.
31. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, Baheiry S, Ruskin J, Reddy V, Natale A,: Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63: 982-988.
32. ClinicalTrials.gov: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (VENTURE-AF). [Internet]. 2013 [cited 2013 Dec 3].Available from: http://clinicaltrials.gov/ct2/show/NCT01729871.
33. Weitz JI, Healey JS, Skanes AC, Verma A,: Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 2014; 129: 1688-1694.
34. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, Yan X, Mohanty S, Trivedi C, Bai R, Price J, Horton R, Gallinghouse GJ, Beheiry S, Zagrodzky J, Canby R, Leclercq JF, Halimi F, Scaglione M, Cesarani F, Faletti R, Sanchez J, Burkhardt JD, Natale A,: Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart 2014; 11: 791-798.
35. Boehringer-Ingelheim Pharmaceuticals. Full Prescribing Information. 2014 [Internet]. 2014 [cited 2014 Apr 23]. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
36. Janssen Pharmaceuticals, Inc. Full Prescribing Information [Internet]. 2011 [cited 2014 Apr 23]. Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf.
37. Bristol-Meyers Squibb Company. Full Prescribing Information. [Internet]. 2012 [cited 2014 Apr 23]. Available from: http://packageinserts.bms.com/pi/pi-eliquis.pdf.
38. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM,; ENGAGE AF-TIMI 48 Investigators: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
39. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S,: Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753.
40. Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, Takami M, Itoh M, Fujiwara R, Suzuki A, Nakanishi T, Yamashita S, Matsumoto A, Hirata K-I,: Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: Efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol 2013; 37: 223-231.
41. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S,: Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig 2013; 33: 409-418.
42. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, Hayano M, Nishiuchi S, Fuke E, Miki Y, Nakamura K, Yamashita E, Kumagai K, Oshima S, Tada H,: Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012; 76: 2337-2342.